Gefitinib were not considered clinically relevant

There were no statistically significant differences in the mean percent baseline slopes over the 6 h of testing, and any Gefitinib differences were not considered clinically relevant. The only statistically significant change was the 27 increase from the baseline at the 2 h time point for the LOP RTV slope. Pupillary response. The mean pupil diameter to iris diameter ratio at the  baseline prior to LOP administration on day 1 was not different from the mean ratio at the baseline prior to the administration of LOP TPV RTV on day 22. Administration of LOP alone or LOP TPV RTV did not affect this ratio. There was no Sunitinib statistically significant difference between the pupillary response, as measured by the baseline mean pupil diameter to iris diameter ratio SEM, prior to the Rapamycin administration of LOP alone on day 1 versus those prior to the administration of LOP TPV or LOP RTV on day 9. With both treatments, no change in the pupil diameter to iris diameter ratio with time after drug treatment was observed. The mean pupillary responses for LOP TPV and LOP RTV were within 2 standard errors of the mean compared to that for LOP alone over the 6 h of testing. Pharmacokinetics. The PK parameters of LOP and its metabolite, N demethyl loperamide, in the presence of TPV, RTV, and TPV RTV are shown in Table 3. Tipranavir and TPV RTV resulted in significant decreases in the AUC from time zero to infinity and Cmax for LOP and LOP metabolite. In contrast, these PK parameters increased in the presence of RTV coadministration. Since the LOP metabolite concentrations also decreased in the presence of TPV and TPV RTV, the increased clearance for LOP in the presence of TPV or TPV RTV can be attributed to a reduction in systemic bioavailability. The effects of single dose LOP on the steady state PK of TPV RTV were assessed by comparing the PK of TPV RTV alone on day 21 to the steady state PK of TPV RTV plus LOP on day 22. Table 4 demonstrates that only Cp12 h for TPV was affected by LOP coadministration. For RTV, however, Cp12 h, Cmax, and AUC0 12 were decreased in the presence of LOP by 30 , 28 , and 22 , respectively. Safety. Adverse events. Overall, 70.8 of the subjects experienced AEs during the TPV RTV treatment period, whereas 37.5 , regardless of causality, experienced AEs during the period of administration of LOP alone. The most frequently observed AEs during TPV RTV treatment, regardless of causality, were loose stools, nausea, abdominal pain, headache, vomiting, dyspepsia, and maculopapular rash. With LOP alone, the most frequently observed AEs were headache and constipation. While taking TPV RTV, 66.7 of the subjects experienced AEs considered treatment related, whereas 25 of the subjects experienced AEs considered treatment related COX Inhibitors while taking LOP alone. None of the adverse events were considered serious or severe, and no subjects were withdrawn from the study because of adverse events.

Related Products

Cat.No. Product Name Information Publications Customer Product Validation
S1025 Gefitinib (ZD1839) Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway. (537) (14)

Related Targets